PHARNEXT SCA
Pharnext Press Release
PharnextAnnounces Issuance of New Composition of Matter PatentsCovering First-in-Class PLEODRUG(TM) PXT3003 and PXT864
PARIS, France, 7:30am, July182018 (CEST)-Pharnext SA (FR0011191287 - ALPHA) a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, today announced the issuance of composition of matter patents,securingprotection as new entities, for two PLEODRUG(TM) products,PXT3003 and PXT864.
"These issued patents confirm the recognitionby the patent offices of Pharnext's innovative drug combinations -or PLEODRUG(TM)- as new products," said Prof. Daniel Cohen, M.D., Ph.D., Pharnext's Co-Founder and Chief Executive Officer. "The patentscontribute to the strength of Pharnext's long-term intellectual property portfoliocoverage forPXT3003 and PXT864, which are already well advanced in development."
The Canadian Intellectual Property Office (CIPO) issued a composition of matterpatent (No. CA2763495)forPXT3003, which expires in 2030. This patent provides protection for PXT3003 perse, not limited to any therapeutic application,andprotects its use in the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A).
The European Patent Office issued a composition of matter patent (No. EP2796132) for PXT864, which expires in 2032. This patent provides protection for PXT864perse, and is not limited to any therapeutic application.
The issuance of these Canadian and European patents further contributes to Pharnext'srobust intellectual property portfolio covering PXT3003 and PXT864. Similar composition of matter patentshave been granted in the U.S., Europe and Japan for PXT3003, and in the U.S. and Japan for PXT864.These patentsfurther confirm Pharnext's innovative drug developments are covered by the same level of robust protection as traditional new chemical entities.
In total, Pharnext's research and development platform has produced a patent portfolio comprising over 540 issued patents covering key pharmaceutical markets.
About Pharnext Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected by October 2018. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY(TM). The Company identifies and develops synergic combinations of drugs called PLEODRUG(TM) offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287). For more information, visit http://www.pharnext.com/
CONTACTS:
Regulatory filing PDF file Document title: VA Document: http://n.eqs.com/c/fncls.ssp?u=YEPEAYCOFG |
705501 18-Jul-2018 CET/CEST
